International travel to tropical regions increasingly exposes visitors to dengue and chikungunya viruses, yet health authorities across developed nations provide starkly different vaccination guidance for these mosquito-borne threats. This regulatory inconsistency leaves travelers and healthcare providers navigating conflicting recommendations for recently approved vaccines that carry significant safety considerations.
A comprehensive analysis of vaccination policies from WHO, ECDC, CDC, and eight national health authorities reveals substantial disagreement on when to use Qdenga (dengue) and IXCHIQ (chikungunya) vaccines. Most countries restrict Qdenga to travelers with laboratory-confirmed prior dengue infection, despite broader regulatory approval in some jurisdictions. IXCHIQ faces even greater scrutiny following reports of severe neurological adverse events, including encephalitis cases and one fatality, prompting the FDA to suspend the vaccine's license in August 2025.
This fragmented approach reflects genuine scientific uncertainty about risk-benefit profiles in travel medicine. Dengue vaccination carries unique complexities because the vaccine can potentially worsen disease in individuals without prior natural infection—a phenomenon requiring laboratory confirmation that many travelers lack. Chikungunya vaccination decisions became more conservative as post-market surveillance revealed serious neurological risks not fully apparent in clinical trials. The divergent national responses highlight how regulatory agencies weigh the same safety data differently, particularly when dealing with vaccines intended for healthy travelers rather than endemic populations. This inconsistency ultimately undermines evidence-based travel health counseling and suggests urgent need for harmonized international vaccination frameworks.